Chen et al.2019[12]
|
Roxadustat vs Epoetin
|
26 weeks
|
Ⅲ, China
|
Starting dose: 100 mg (45-60 kg)
or 120 mg (≥60 kg) TIW
|
10.40 ± 0.70/10.50 ± 0.70
|
47.6±11.7/51.0±11.8
|
204 (126/78)
|
100 (58/42)
|
Akizawa et al.2020a[26] |
Roxadustat vs Darbepoetin |
24 weeks |
Ⅲ,
Japan |
Starting dose: 70 or 100 mg TIW |
11.02 ± 0.56/11.01 ± 0.60 |
64.6±11.7/64.9±10.1 |
150 (101/49) |
151 (107/44) |
Provenzano et al.2021[27]
|
Roxadustat vs Epoetin
|
52 weeks
|
Ⅲ, Global
|
Starting dose: 70 mg (<70 kg)
or 100 mg (≥70 kg) TIW
|
8.43 ± 1.04/8.46 ± 0.96
|
53.8±14.7/54.3±14.6
|
522 (309/213)
|
521 (307/214)
|
Hou et al.2021[28]
|
Roxadustat vs. ESAs
|
24 weeks
|
Ⅲ, China
|
Starting dose: 100 mg (45-60 kg)
or120 mg (≥60 kg) TIW
|
9.00 ± 1.40/9.00 ± 1.20
|
48.0±12.0/48.3±13.0
|
86 (47/39)
|
43 (25/18)
|
Csiky et al.2021[29] |
Roxadustat vs Daebepotin |
52 weeks |
Ⅲ,
Global |
Starting dose: 20, 50 and 100mg TIW |
10.75 ± 0.62/10.78 ± 0.62 |
61.0±13.8/61.8±13.4 |
414 (245/169) |
420 (235/185) |
Charytan et al.2021[30] |
Roxadustat vs Epoetin |
52 weeks |
Ⅲ, US |
Starting dose: 70-200mg TIW based on the pre-study ESA dose |
10.30 ±
0.66 10.31 ± 0.66 |
57.6±13.6/58.4±13.3 |
370 (187/183) |
371
(215/156) |
Fishbane et al. 2022[16]
|
Roxadustat vs Epoetin
|
4 years
|
Ⅲ, Global
|
Starting dose: ESAs naive:70mg(45-70kg)
or 100 mg (70-160 kg) TIW
ESAs users:70-200 mg TIW
|
10.10 ± 0.80/10.10 ± 0.90
|
53.5±15.3/54.5±15.0
|
1051 (625/426)
|
1055 (626/429)
|
Singh et al.2021[31] |
Daprodustat vs Epoetin |
21 months |
Ⅲ, Global |
Starting dose: 4-12mg q. d. |
10.35 ± 0.97/10.39 ± 0.98 |
57.2±14.3/57.3±14.7 |
1487 (851/636) |
1477 (847/630) |
Meadowcroft et al.2019[32] |
Daprodustat vs rhEPO, ESAs |
24 weeks |
Global |
Starting dose: 4-12mg q. d. |
10.40 ± 0.66/10.60 ± 0.94 |
59.6±13.3/59.7±18.7 |
171 (108/63) |
39 (26/13) |
Akizawa et al. 2020b[33] |
Daprodustat vs Darbepoetin |
52 weeks |
Ⅲ, Japan |
Starting dose: 4mg q. d. |
10.90 ± 0.80/10.80 ± 0.70 |
64.0±10.0/64.0±11.0 |
136 (91/45) |
135 (89/46) |
Singh et al.2022[34] |
Daprodustat vs Darbepoetin |
52 weeks |
Ⅲ,
Global |
Starting dose: 1-24mg q. d. |
9.50 ± 0.10/9.50 ± 0.10 |
53.7±14.3/55.8±15.7 |
157 (96/61) |
155 (98/57) |
Coyne et al.2022[35]
|
Daprodustat vs Epoetin
|
52 weeks
|
Ⅲ, Global
|
Starting dose: 2-48mg
TIW
|
10.44 ± 0.83/10.59 ± 0.93
|
60 (50–69)/56 (46.5–65.5)
|
270 (149/121)
|
137 (81/56)
|
Eckardt et al.2021[2]
|
Vadadustat vs Darbepoetin
|
52 weeks
|
Ⅲ, Global
|
Starting dose: 300mg q. d.
Maintenance dose: 150-600mg q. d.
|
9.40 ± 1.10/9.20 ± 1.10
|
56.5±14.8/55.6±14.6
|
181 (107/74)
|
188 (113/75)
|
Eckardt et al.2021[2]
|
Vadadustat vs Darbepoetin
|
52 weeks
|
Ⅲ, Global
|
Starting dose: 300mg q. d.
Maintenance dose: 150-600mg q. d.
|
10.60 ± 0.90/10.20 ± 0.80
|
57.9±13.9/58.4±13.8
|
1777 (990/787)
|
1777 (1004/773)
|
Nangaku et al.2021[36]
|
Vadadustat vs Darbepoetin
|
52 weeks
|
Ⅲ, Japan
|
Starting dose: 300mg q. d.
Maintenance dose: 150-600mg q. d.
|
10.73 ± 0.70/10.73 ± 0.70
|
66.0±11.3/64.9±11.7
|
162 (104/58)
|
161 (109/52)
|
Macdougall et al.2019[37] |
Molidustat vs Epoetin |
16 weeks |
Ⅱb, US and Japan |
Starting dose: 25-150mg |
10.50 ± 0.60/10.60 ± 0.50 |
59.0±13.0/59.0±9.0 |
157 (91/66) |
42 (29/13) |
Akizawa et al.2019[38] |
Molidustat vs Epoetin |
52 weeks |
Ⅱb,
Global |
Starting dose: 15-150mg q. d. |
10.40 ± 0.70/10.50 ± 0.50 |
61.0±12.0/59.0±9.0 |
57 (33/24) |
30 (23/7) |
Akizawa et al.2021[40]
|
Molidustat vs Darbepoetin
|
52 weeks
|
Ⅲ, Japan
|
Starting dose: ESAs naive:75mg q. d.
user: 100/125/150mg based on prior ESA dose
|
10.79±0.65/10.87±0.64
|
66.2±10.3/64.8±10.6
|
153(91/62)
|
76(49/27)
|
Akizawa et al.2021[39] |
Enarodustat vs Darbepoetin |
24
weeks |
Ⅲ, Japan |
Starting dose: 4mg q. d. |
10.79 ± 0.65/10.87 ± 0.70 |
63.2±10.8/64.8±10.3 |
86 (61/25) |
86 (61/25) |
Gang et al.2022[41] |
Desidustat vs Epoetin |
24 weeks |
Ⅲ, India |
Starting dose: 100mg TIW |
9.61±0.99/9.55±1.37 |
51.0±14.0/51.0±13.5 |
196(135/61) |
196(134/62) |